Cholecystokinin
- CAS No.
- 9011-97-6
- Chemical Name:
- Cholecystokinin
- Synonyms
- CCK;RICK;RIPK2;RIP2;CARD3;GIG30;CARDIAK;PANCREOZYMIN;kinase RIPK2;CHOLECYSTOKININ
- CBNumber:
- CB9410022
- Molecular Formula:
- C166H261N51O52S4
- Molecular Weight:
- 0
- MDL Number:
- MFCD00131790
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| storage temp. | 2-8°C |
|---|---|
| form | buffered aqueous glycerol solution |
| color | White to off-white |
| Specific Activity | 17-23nmol/min·mg |
| Sequence | Lys-Ala-Pro-Ser-Gly-Arg-Met-Ser-Ile-Val-Lys-Asn-Leu-Gln-Asn-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser-Asp-Arg-Asp-{Tyr(SO3H)}-Met-Gly-Trp-Met-Asp-Phe-NH2 |
| EWG's Food Scores | 1 |
| FDA UNII | 00XI8W60QF |
| ATC code | V04CK02 |
| UNSPSC Code | 51111800 |
| NACRES | NA.32 |
SAFETY
Risk and Safety Statements
| PPE | Eyeshields, Gloves, multi-purpose combination respirator cartridge (US) |
|---|---|
| WGK Germany | 3 |
| Storage Class | 10 - Combustible liquids |
Cholecystokinin price More Price(13)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | R1406 | RIPK2 (1-299), active, GST tagged human PRECISIO? Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution | 9011-97-6 | 10μG | $490 | 2026-04-30 | Buy |
| Usbiological | 545885 | Cholecystokinin PurifiedbyProteinAandpeptideaffinitychromatography. | 200ul | $545 | 2026-06-03 | Buy | |
| ChemScene | CS-0143267 | Cholecystokinin 98.16% | 9011-97-6 | 5mg | $812 | 2026-06-04 | Buy |
| ChemScene | CS-0143267 | Cholecystokinin 98.16% | 9011-97-6 | 10mg | $1300 | 2026-06-04 | Buy |
| aablocks | AA029LIU | Cholecystokinin >98% | 9011-97-6 | 5mg | $869 | 2026-06-02 | Buy |
Cholecystokinin Chemical Properties, Uses, Production
Discovery
CCK is released from I-cells in the small intestine. CCK stimulates gall bladder contraction and pancreatic enzyme secretion. In the central nervous system, CCK is implicated in anxiogenesis, satiety, appetite, nociception, memory, and learning. In 1928, CCK was first described as an inducer of gall bladder contractions derived from the small intestines of dogs and cats. Pig intestine extracts were known to contain a substance called pancreozymin, which stimulated the secretion of pancreatic enzymes. In 1962, a 33-aa peptide isolated from pig intestines was reported to activate both gall bladder contractions (CCK action) and pancreatic enzyme secretion (pancreozymin action). The sequence of porcine CCK/pancreozymin was determined in 1968.
Structure
Human preproCCK consists of 115 aa residues. Bioactive peptides of varying lengths with different N-terminal extensions (CCK-58, CCK-33, CCK-22, CCK-12, CCK-8, and CCK-4) are produced by enzymatic processing. CCK possesses a sulfated tyrosine at the seventh residue from the C-terminus. The C-terminal phenylalanine residue is amidated. In vertebrates, the amino acid sequences of CCKs are highly conserved, particularly in the C-terminal sequence that retains biological activity .
Gene, mRNA, and precursor
The human preproCCK gene, CCK, location 3p22.1, contains five exons. CCK mRNA is 1511 bases in length and encodes a precursor of 115 aa residues. The CCK gene is expressed in the I-cells of the duodenum and small intestine. In rats, Cck is expressed in the brain, heart, lung, kidney, and small intestine.
Synthesis and release
In intestinal I-cells, dietary lipids and proteins are sensed by GPR40 and the calcium-sensing receptor, respectively, resulting in the stimulation of CCK release.
Receptors
The CCK1 receptor (CCK1R) and CCK2 receptor (CCK2R) are GPCRs that have seven transmembrane domains. Human CCK1R consists of 428 aa residues. CCK binds to CCK1R with 500 to 1000 times the affinity and potency of gastrin and nonsulfated CCK. The sulfation of CCK is essential for receptor activation. The dissociation constants (Kd) of CCK-8 and nonsulfated CCK-8 with CCK1R are 1 and 500 nM, respectively.
Agonists and Antagonists
CCK, A-71623, GW-5823. Devazepide, Lintitript, Lorglumide, PD-140548, T-0632.
Biological functions
CCK stimulates contraction of the gall bladder and secretion of pancreatic enzymes via CCK1R. CCK affects the vagal afferent neurons in paracrine and endocrine manners via CCK1R and inhibits gastric emptying and food intake. Insulin secretion is induced by CCK stimulation. In the central nervous system, CCK is implicated in anxiogenesis, satiety, appetite, nociception, memory, and learning.
Description
Cholecystokinin is the most widespread and abundant peptide in the brain, with only the mature cerebellum possibly devoid of representation. Interest in this peptide also stems from its potency, prominent colocalization with dopamine, nonsynaptic associations influencing neuronal excitability and cerebral blood flow, and putative links to several neuropsychiatric disorders (Rehfeld 1992a, 1992b).
Uses
Cholecystokinin is a peptide hormone. Cholecystokinin, as a hunger suppressant, inhibits food intake and stimulates the digestion of fat and protein. Cholecystokinin can be used for the research of gastrointestinal system[1][2][3].
General Description
Receptor interacting serine/threonine kinase 2 (RIPK2) or RICK is a serine/threonine kinase. It contains a kinase domain at the amino-terminal, an intermediate domain and a caspase activation and recruitment domain (CARD) at the carboxy-terminal. The gene encoding RIPK2 is localized on human chromosome 8q21.3.
Biochem/physiol Actions
Receptor interacting serine/threonine kinase 2 (RIPK2) or RICK is activated during innate immune responses and acts as a scaffold for downstream effectors. It functions in nuclear factor-κB (NFκB) activation pathways. The protein also has roles in toll-like receptor (TLR)-signaling pathways and in the production of inflammatory cytokines.
References
[1] G P Smith, et al. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science. 1981 Aug 28;213(4511):1036-7. DOI:10.1126/science.7268408
[2] R A Liddle, et al. Cholecystokinin cells. Annu Rev Physiol. 1997;59:221-42. DOI:10.1146/annurev.physiol.59.1.221
[3] Dockray, Graham J. Cholecystokinin. Curr Opin Endocrinol Diabetes Obes. 2012 Feb;19(1):8-12. DOI:10.1097/MED.0b013e32834eb77d
Cholecystokinin Preparation Products And Raw materials
Raw materials
Preparation Products
Cholecystokinin Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hangzhou Peptidego Biotech Co.,Ltd. | 0571-87213919 15967184799 | Eric@peptidego.com | China | 7872 | 58 |
| Guangzhou Tomums Life Science Co., Ltd. | 020-31155029 18902330969 | sales@tomums.cn | China | 4688 | 58 |
| Hangzhou Go Top Peptide Biotech | 0571-88211921 17357109671 | sales3@gotopbio.com | China | 2988 | 58 |
| Shanghai Universal Biotech Co.,Ltd | 15921930842 15921930842 | yh-wang@univ-bio.com | China | 25030 | 58 |
| Shanghai Yaji Biological Technology Co., Ltd. | 021-34661275 15301693058 | yajikit@163.com | China | 9925 | 58 |
| Hangzhou Sinoda Pharmaceutical Technology Co. LTD | 0571-87213919 17306812703 | 3007955328@qq.com | China | 7446 | 58 |
| Shanghai Huzhen Industrial Co., LTD | 021-60345367 13916550749 | sales@shzbio.com | China | 9965 | 58 |
| Jiangsu Chunhui Medical Technology Co., Ltd | 13913819195 | tangyedong@jshzdl.cn | China | 199 | 58 |
| Shanghai Yubo Biotechnology Co., Ltd | 021-60514606 18321282235 | sale1@shybsw.net | China | 8165 | 58 |
| YantaiBio | 13758194781; 13758194781 | 764619768@qq.com | China | 1773 | 58 |
9011-97-6 (Cholecystokinin) Related Search:
1of4
